Please assess the completion status of the following clinical trial:

Trial Title: A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age at least 18 years.~2. Documented evidence of NSCLC (locally advanced, unresectable, Stage III)~3. Patients must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy.~4. World Health Organisation (WHO) Performance Status of 0 to 1.~5. Estimated life expectancy of more than 12 weeks.~Exclusion Criteria:~1. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.~2. Active or prior autoimmune disease or history of immunodeficiency.~3. Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.~4. Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.~5. Any unresolved toxicity CTCAE \>Grade 2 from the prior chemoradiation therapy.~6. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- MEDI4736 (Type: EXPERIMENTAL): MEDI4736 (intravenous infusion)
- PLACEBO (Type: PLACEBO_COMPARATOR): Placebo (matching placebo for intravenous infusion)

Based on this trial design, predict the completion outcome and termination type (if applicable).